---
layout: post
title: "Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-01705
original_published: 2020-01-30 00:00:00 +0000
significance: 8.00
---

# Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 30, 2020 00:00 UTC
**Document Number:** 2020-01705

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled "Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations." The draft guidance document provides FDA's current thinking on the criteria to determine sameness of human gene therapy products for the purpose of orphan drug designation and orphan drug exclusivity. The draft guidance is intended to assist stakeholders, including industry and academic sponsors who seek orphan drug designation and orphan drug exclusivity, in the development of gene therapies for rare diseases.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/30/2020-01705/interpreting-sameness-of-gene-therapy-products-under-the-orphan-drug-regulations-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2020-01705

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
